MBX Biosciences, Inc. (MBX) income statement
MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$53.42+0.32 (+0.60%)
Close on Nov 18, 2026Market cap $2.57BP/E –Yield –
MBX Biosciences, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -27.8%
Financial strength
- Current ratio
- 19.58
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 642.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.44
- Dividend yield
- –
See a number that looks wrong?